ArticleRetrovirology2017
Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.
Article in Retrovirology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 67 citations in OpenAlex.
- Isolation of Brain Microglia to Study Persistence of Human Immunodeficiency Virus-1.Journal of visualized experiments : JoVE · 2026Article
- Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND).Biomolecules · 2026Review
- Article
- High concordance of human immunodeficiency virus-1 genotypic drug resistance generated from paired cerebrospinal fluid and plasma in antiretroviral therapy -naive or -experienced patients.Frontiers in microbiology · 2025Article
- In situ analysis of neuronal injury and neuroinflammation during HIV-1 infection.Retrovirology · 2024Article
- Ionic Liquid Coating-Driven Nanoparticle Delivery to the Brain: Applications for NeuroHIV.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading?Viruses · 2024Review
- Review
- Differences in drug resistance of HIV-1 genotypes in CSF and plasma and analysis of related factors.Virulence · 2023Article
- Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations.Molecules (Basel, Switzerland) · 2023Article
- HIV-1 Tat Upregulates TREM1 Expression in Human Microglia.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment.Biochemistry and biophysics reports · 2023Article
- Ionic Liquid Coating-Driven Nanoparticle Delivery to the Brain: Applications for NeuroHIV.Research square · 2023Article
- The HIV Restriction Factor Profile in the Brain Is Associated with the Clinical Status and Viral Quantities.Viruses · 2023Article
- A Rationale and Approach to the Development of Specific Treatments for HIV Associated Neurocognitive Impairment.Microorganisms · 2022Review
- The potential role of HIV-1 latency in promoting neuroinflammation and HIV-1-associated neurocognitive disorder.Trends in immunology · 2022Review
- Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Meditation and Aerobic Exercise Enhance Mental Health Outcomes and Pattern Separation Learning Without Changing Heart Rate Variability in Women with HIV.Applied psychophysiology and biofeedback · 2022Article
- Is HIV Brain Disease Preventable?Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Human microglial models to study HIV infection and neuropathogenesis: a literature overview and comparative analyses.Journal of neurovirology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with HIV/AIDS receiving antiretroviral therapy (ART), HIV-1 persistence in brain tissue is a vital and unanswered question. HIV-1 infects and replicates in resident microglia and trafficking macrophages within the brain although the impact of individual ART drugs on viral infection within these brain myeloid cells is unknown. Herein, the effects of contemporary ART drugs were investigated using in vitro and in vivo models of HIV-1 brain infection.
resultsThe EC
conclusionsART drugs show variable concentrations and efficacies in brain myeloid cells and tissues in drug-specific manner. Despite low drug concentrations in brain, experimental ART suppressed HIV-1 infection in brain although HIV/AIDS patients receiving effective ART had detectable HIV-1 in brain. These findings suggest that viral suppression in brain is feasible but new approaches to enhancing ART efficacy and concentrations in brain are required for sustained HIV-1 eradication from brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.